

Program

Vaccines Summit-2024 | November 13-15 | Boston, MA

Keynote Presentations | Day-1 Nov-13 | GrandBall Room

EST (Eastern Time Zone)

Exhibitors



Registrations

Introduction: Opening Ceremony

Chair

David Weiner, Executive Vice President, The Wistar Institute, Director, Vaccine & Immunotherapy Center

- 08:00-08:30 Presentation Title: **Human *in vitro* modeling and systems biology to advance precision vaccines**
Ofer Levy, Staff Physician & Principal Investigator, Director, Precision Vaccines Program, Division of Infectious Diseases, Boston Children's Hospital Professor, Harvard Medical School
- 08:30-09:00 Presentation Title: **Correlates of protection for COVID-19 and Mpox vaccines**
Dan Barouch, Director, Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center
- 09:00-09:30 Presentation Title: **Tailoring vaccine immunity and immune therapy by novel nucleic acid tools incorporating potent delivery and unique formulations**
David Weiner, Executive Vice President, The Wistar Institute, Director, Vaccine & Immunotherapy Center
- 09:30-10:00 Presentation Title: **Efficacy of dendritic-cell-based cancer vaccines enhanced by development in high omega-3 lipid environment**
Jay A. Berzofsky, Chief, Vaccine Branch, Center for Cancer Research, National Cancer Institute, NIH
- Sponsored by Cellular Technology Limited** **Coffee Break 10:00-10:30**
- 10:30-11:00 Presentation Title: **End-to-end development of VSV-based vaccines for outbreak and epidemic preparedness: the road traveled thus far**

Swati Gupta, VP, Emerging Infectious Diseases and Epidemiology, IAVI

- 11:00-11:30 Presentation Title: **Regulatory perspective on frontiers in vaccine development**
David Kaslow, Director, Office of Vaccines Research and Review, FDA/CBER
- 11:30-12:00 Presentation Title: **RSV vaccine for maternal immunization: Why did it take more than 60 years?**
William C. (Bill) Gruber, Gruber Vaccine R&D Consulting, LLC
- 12:00-12:30 Presentation Title: **Accelerating site selection and recruitment for vaccines with AI/ML: From COVID-19 to Beyond**
Michael Lingzhi Li, Technology and Operations Management Unit, Harvard Business School
- 2:00-2:30 Presentation Title: **Advancement in *Leishmania* vaccination development and its role in global elimination of leishmaniasis**
Hira Nakhasi, Division Director – DETTD, Center for Biologics Evaluation and Research
- 2:30-3:00 Presentation Title: **Next generation mRNA design – increasing mRNA potency**
Heather Schultheisz, Director of Innovation, Maravai LifeSciences
- 3:00-3:30 Presentation Title: **Universal vaccines against influenza and other pathogens**
Jerry Sadoff, Chief Medical Officer, Centivax
- 3:30-4:00 Presentation Title: **How to develop long-lasting vaccines against tough pathogens**
Gongyi Zhang, Professor, Department of Immunology and Genomic Medicine, National Jewish Health
- 4:00-4:30 Presentation Title: **DNA medicines platform for both prophylactic and therapeutic applications: case studies in Ebola and recurrent respiratory papillomatosis**
Dave Liebowitz, Senior Vice President, Early-Stage Clinical Development, INOVIO
- 4:30-5:00 Presentation Title: **Genomic integration of SARS-CoV-2 sequences in virus infected and viral RNA transfected human cells**
Rudolf Jaenisch, Professor of Biology, Whitehead Institute, MIT

5:00-6:00

Reception @ Foyer Area

5:00-6:00

Poster Presentations

Characterization and comparison of immunity against MPXV for individuals infected with MPXV or vaccinated with modified vaccinia Ankara vaccines
Aurelie Wiedemann, INSERM/VRI

Conjugated pneumococcal vaccination yields broadly functional, mucosal-directed responses in aged adults
Qixin Wang, Ragon Institute of MGH, MIT and Harvard

Monovalent XBB.1.5 mRNA vaccine recalls a more durable and coordinated antibody response to SARS-CoV-2 spike than the bivalent WT/BA.5 mRNA vaccine

Ryan McNamara, Harvard T. H. Chan School of Public Health

Development of a Marburg self-amplifying mRNA-lipid nanoparticle vaccine: differential immune responses when co-formulated with toll-like receptor agonists

Erik de Leeuw, Labcorp

Conjugate vaccine | DAY-2 Nov-14 | GrandBall Room

Chair Andrew Lees, CEO/CSO, Fina Biosolutions

Co-Chair Robert van der Put, Director Business Development, Intravacc

08:00-08:30 Presentation Title: **Overview of conjugate vaccines and conjugate vaccine development**
Andrew Lees, CEO/CSO, Fina Biosolutions

08:30-09:00 Presentation Title: **Turbo: an adjuvant platform for bacterial glycoconjugate vaccines**
Kishore Alugupalli, Founder & Chief Executive Officer, TurboVax Inc

09:00-09:30 Presentation Title: **Data in the target population for a *Shigella flexneri* 2a glycoconjugate support the development of a broad serotype coverage synthetic glycan-based vaccine candidate for shigellosis**
Laurence A. Mulard, Institut Pasteur

09:30-10:00 Presentation Title: **Development of the first quadrivalent synthetic oligosaccharide-based conjugate vaccine against *Shigella***
Fiona Lin, Vaccine Process Development and Manufacturing Lead, GATES MRI

Coffee Break 10:00-10:30

10:30-11:00 Presentation Title: **A modular vaccine platform for prophylactic and therapeutic vaccines: exogeneous decoration of bacterial outer membrane vesicles with synthetic peptide antigens**
Robert van der Put, Director Business Development, Intravacc

11:00-11:30 Presentation Title: **Design of a glycoconjugate vaccine against *Salmonella Paratyphi A***
Renzo Alfini, Senior Scientist, GVGH Preclinical – Vaccine Chemistry, GSK Vaccines Institute for the Global Health

11:30-12:00 Presentation Title: **Study of CDAP chemistry as generic conjugation for development of glycoconjugate vaccines**
Carlo Giannelli, Lab Head Vaccine Chemistry, GSK Vaccines Institute for the Global Health

12:00-12:30 Presentation Title: ***In vivo* polysaccharide protein conjugation using *E. coli* as host with a next generation conjugating enzyme system**
Christian Harding, Omniose

Lunch 12:30-1:30

1:30-2:00 Presentation Title: **The fentanyl epidemic: costs, currency, and who pays the check**
Shon Remich, Chief Medical Officer, Ovax

2:00-2:30 Presentation Title: **Heroin and fentanyl vaccines adjuvanted with army liposome formulation**
Gary R. Matyas, Chief, Adjuvants and Formulation, US Military HIV Research Program, Walter Reed Army Institute of Research

DAY-2 Nov-14 | GrandBall Room

Session Chair Xingmin Sun, University of South Florida

2:30-3:00 Presentation Title: **Durability of antibody responses following SARS-CoV-2 booster vaccination**
Mehul S. Suthar, Associate Professor, Emory Vaccine Center, Emory University

3:00-3:30 Presentation Title: **Computational design of a potent pre-fusion protein as a human metapneumovirus vaccine**
Michael Kishko, Principal Scientist, Global Antigen Design, Sanofi

3:30-4:00 Presentation Title: **The state of herpes simplex virus vaccine R&D**
Simon Delagrave, Herpes Cure Advocacy

4:00-4:30 Presentation Title: **A simple, safe, affordable, and scalable intracellular delivery platform for “naked” RNA/DNA vaccines and therapeutics**
Eleftheria Michalaki, Senior Scientist, Piezo Therapeutics

Coffee Break 4:30-5:00

5:00-5:30 Presentation Title: **Recombinant fusion protein vaccine containing *Clostridioides difficile* FliC and FliD protects mice against *C. difficile* infection**
Xingmin Sun, Professor, Dept. of Molecular Biosciences; Dept. of Chemistry, University of South Florida

5:30-6:00 Presentation Title: **Preclinical studies on single injection slow-released silica matrix HIV-protein trimer vaccine**
Milla RUNSALA, Business Development Manager, DelSiTech Ltd

6:00-6:30 Presentation Title: **Whole-cell *Acinetobacter baumannii* vaccine candidates induce a protective response and appear well-tolerated in mice**
Stephen J. Dollery, Director of Research and Development, Biological Mimetics, Inc

6:30-7:00 Presentation Title: **Swift defense, long offense: rVSV-based vaccines against Nipah and Lassa viruses**
Courtney Woolsey, Assistant Professor of Microbiology and Immunology, University of Texas Medical Branch

7:00-7:30 Presentation Title: **Adaptive immunity to *Bordetella pertussis* in vaccination and infection**
Ricardo da Silva Antunes, Instructor at La Jolla Institute for Immunology

7:30-8:30 Happy Hours Sponsored by Fina Biosolutions

| **DAY-3 Nov-15** | **GrandBall Room**

Session Chair **Robert O. Dillman**, Chief Medical Officer, AIVITA Biomedical, Inc.

Cancer Vaccines & Immunotherapy

08:00-08:30 Presentation Title: **A platform for personal cancer vaccine immunotherapy targeting tumor-initiating cells**

Robert O. Dillman, Chief Medical Officer, AIVITA Biomedical, Inc.

08:30-09:00 Presentation Title: **Antigen-specific B-cell ELISPOT evaluation in immunotherapies**

Andrea Maul-Pavicic, Scientist, CRO, Cellular Technology Limited

09:00-09:30 Presentation Title: **Novel biologics platform for antigen-specific T cell modulation**

Steven Almo, Chair, Department of Biochemistry, Albert Einstein College of Medicine

09:30-10:00 Presentation Title: **T-cell signalling pathways that enhance chimeric antigen receptor (CAR) therapy against in cancer**

Christopher E. Rudd, Professeur, Faculte de Medicine, Universite de Montreal

Coffee Break 10:00-10:30

Session Chair **Zhaohua Zhou**, Senior Scientist, Office of Pharmaceutical Quality Research, CDER/FDA

Coronavirus (COVID-19)

10:30-11:00 Presentation Title: **SARS-CoV-2 B epitope-guided neoantigen nanovaccines enhance tumor-specific CD4/CD8 T cell immunity through B cell antigen presentation**

Duxin Sun, Director of Pharmacokinetics Core, The University of Michigan

11:00-11:30 Presentation Title: **The secreted SARS-CoV-2 ORF8 protein drives a systemic pro-inflammatory cytokine response via NLRP3 pathways in patients with severe COVID-19**

Xiaosheng Wu, Assistant Professor, Hematology Research, Mayo Clinic Rochester

11:30-12:00 Presentation Title: **Hypersensitivity caused by mRNA/LNP COVID vaccines: Role of PEG and anti-PEG antibodies**

Zhaohua Zhou, Senior Scientist, Office of Pharmaceutical Quality Research, CDER/FDA

12:00-12:30 Presentation Title: **From light to insight: Harnessing bioluminescence imaging to track SARS-CoV-2 spread and antiviral therapies in mouse models**

Pradeep D. Uchil, Research Scientist, Yale University School of Medicine

12:30-1:00 Presentation Title: **Immunogenicity and protective efficacy of RSV G central conserved domain vaccine with a prefusion nanoparticle**

Linong Zhang, Sanofi

Lunch 1:00-2:00

2:00-2:15 Presentation Title: **A pre-immune ferret model for influenza demonstrates enhanced neutralizing antibody titers following vaccination**

Ashley C. Beavis, Sanofi Vaccine Research and Development

- 2:15-2:45 Presentation Title: **Long-term cellular immunity of vaccines for Zaire Ebola virus diseases**
Aurelie Wiedemann, Vaccine Research Institute / Inserm
- 2:45-3:15 Presentation Title: **Targeting Langerhans cells using trimeric Env of HIV triggers a swift and robust production of Env-specific IgG antibodies and neutralizing antibodies through a Tfh/germinal center (GC) reaction**
Sylvain Cardinaud, Vaccine Research Institute / Inserm
- 3:15-3:45 Presentation Title: **Providing solution for novel vaccine development and manufacturing for a healthier 21st century**
Xinhao Ye, Director, CMC lead of WuXi Vaccines

Coffee Break 3:45-4:30

END OF THE PROGRAM